Background Subcutaneous administration of the monoclonal antibody L9LS protected adults
against controlled Plasmodium falciparum infection in a phase 1 trial. Whether a monoclonal …

Malaria remains one of the biggest health problems in the world. While significant reductions
in malaria morbidity and mortality had been achieved from 2000 to 2015, the favorable trend …

Malaria remains one of the most important infectious diseases in the world, with the greatest
burden in sub-Saharan Africa, primarily from Plasmodium falciparum infection. The …

Summary Background The R21/Matrix-M vaccine has demonstrated high efficacy against
Plasmodium falciparum clinical malaria in children in sub-Saharan Africa. Using trial data …

Background A blood-stage Plasmodium falciparum malaria vaccine would provide a second
line of defence to complement partially effective or waning immunity conferred by the …

Ensuring that malaria vaccines deliver maximum public health impact is non-trivial. Drawing
on current research, this article examines hurdles that malaria immunization may face to …

Malaria killed over 600,000 people in 2022, a death toll that has not improved since 2015.
Additionally, parasites and mosquitoes resistant to existing interventions are spreading …

Malaria, caused by infection with Plasmodium parasites, drives multiple regulatory
responses across the immune landscape. These regulatory responses help to protect …

The highly conserved and essential Plasmodium falciparum reticulocyte-binding protein
homolog 5 (PfRH5) has emerged as the leading target for vaccines against the disease …

Die STIKO empfiehlt Reiseimpfungen zum individuellen Schutz Reisender mit einem
Expositionsrisiko gegenüber bestimmten impfpräventablen Erkrankungen und um den …